Amneal (AMRX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
2.8B
Gross Profit
1.0B
36.52%
Operating Income
347.4M
12.44%
Net Income
-73.9M
-2.64%
EPS (Diluted)
-$0.38
Balance Sheet Metrics
Total Assets
3.5B
Total Liabilities
3.6B
Shareholders Equity
-109.5M
Cash Flow Metrics
Operating Cash Flow
136.9M
Free Cash Flow
220.1M
Revenue & Profitability Trend
Amneal Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2.8B | 2.4B | 2.2B | 2.1B | 2.0B |
| Cost of Goods Sold | 1.8B | 1.6B | 1.4B | 1.3B | 1.4B |
| Gross Profit | 1.0B | 820.6M | 784.7M | 769.0M | 628.4M |
| Operating Expenses | 673.0M | 596.3M | 595.8M | 575.1M | 517.3M |
| Operating Income | 347.4M | 224.2M | 188.9M | 193.9M | 111.1M |
| Pre-tax Income | -55.0M | -40.3M | -248.1M | 31.4M | -35.8M |
| Income Tax | 18.9M | 8.5M | 6.7M | 11.2M | -104.4M |
| Net Income | -73.9M | -48.7M | -254.8M | 20.2M | 68.6M |
| EPS (Diluted) | -$0.38 | -$0.48 | -$0.86 | $0.07 | $0.61 |
Income Statement Trend
Amneal Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.6B | 1.4B | 1.4B | 1.5B | 1.6B |
| Non-Current Assets | 1.9B | 2.1B | 2.4B | 2.4B | 2.5B |
| Total Assets | 3.5B | 3.5B | 3.8B | 3.9B | 4.0B |
| Liabilities | |||||
| Current Liabilities | 1.1B | 846.6M | 752.8M | 677.2M | 676.9M |
| Non-Current Liabilities | 2.5B | 2.6B | 2.9B | 2.9B | 3.0B |
| Total Liabilities | 3.6B | 3.5B | 3.6B | 3.6B | 3.7B |
| Equity | |||||
| Total Shareholders Equity | -109.5M | 20.0M | 184.0M | 367.0M | 344.9M |
Balance Sheet Composition
Amneal Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -73.9M | -48.7M | -254.8M | 20.2M | 68.6M |
| Operating Cash Flow | 136.9M | 157.1M | -37.2M | 187.9M | 248.4M |
| Investing Activities | |||||
| Capital Expenditures | -60.3M | -46.8M | -48.8M | -50.9M | -61.8M |
| Investing Cash Flow | -48.3M | -46.8M | -132.5M | -192.5M | -313.2M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -212.9M | -213.0M | -107.3M | -139.0M | 131.5M |
| Free Cash Flow | 220.1M | 276.4M | -25.5M | 189.2M | 312.8M |
Cash Flow Trend
Amneal Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
89.83
Forward P/E
11.15
Price to Book
-41.46
Price to Sales
1.30
PEG Ratio
11.15
Profitability Ratios
Profit Margin
-0.46%
Operating Margin
14.51%
Return on Equity
106.73%
Return on Assets
6.67%
Financial Health
Current Ratio
1.40
Debt to Equity
-43.43
Beta
1.06
Per Share Data
EPS (TTM)
-$0.04
Book Value per Share
-$0.42
Revenue per Share
$9.13
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| amrx | 3.7B | 89.83 | -41.46 | 106.73% | -0.46% | -43.43 |
| Zoetis | 70.3B | 28.34 | 15.12 | 52.09% | 27.12% | 145.63 |
| Haleon Plc - ADR | 47.2B | 25.01 | 5.88 | 8.95% | 12.84% | 63.41 |
| Regencell Bioscience | 18.5B | - | 1,394.12 | -43.18% | 0.00% | 1.04 |
| Elanco Animal Health | 6.6B | 17.80 | 1.04 | 6.01% | 8.43% | 69.18 |
| Lantheus Holdings | 5.6B | 23.07 | 4.81 | 24.11% | 16.55% | 52.78 |
Financial data is updated regularly. All figures are in the company's reporting currency.